Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 216-224

  Lencioni, Riccardo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Hepatocellular carcinoma; Multikinase inhibitors; Sorafenib; Transarterial chemoembolization

Indexed keywords

ALCOHOL; CD135 ANTIGEN; DOXORUBICIN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ALOPECIA; ANOREXIA; ARTIFICIAL EMBOLISM; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CONSERVATIVE TREATMENT; DIARRHEA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; REVIEW; SYSTEMIC THERAPY; THERAPY EFFECT; TUMOR ABLATION; TUMOR BLOOD FLOW; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DRUG DELIVERY SYSTEMS; HUMANS; LIVER; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84864052036     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.10.008     Document Type: Review

References (70)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
3. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
4. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
5. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
6. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
7. Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25:3866-3884.
8. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
9. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
10. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
11. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004, 11:383-393.
12. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
13. Fernandez M., Semela D., Bruix J., et al. Angiogenesis in liver disease. J Hepatol 2009, 50:604-620.
14. Aravalli R.N., Steer C.J., Cressman E.N.K. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063.
15. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 20:1527-1536.
16. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
17. Bruix J., Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
18. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
19. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
20. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
21. Bruix J., Sherman M., Llovet J.M., et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001, 35:421-430.
22. Bertot L.C., Sato M., Tateishi R., Yoshida H., Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 2011, 21:2584-2596.
23. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
24. Lloyd D.M., Lau K.N., Welsh F., et al. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB 2011, 13:579-585. (Oxford).
25. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
26. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67.
27. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
28. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
29. Tamesa T., Iizuka N., Mori N., et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 2009, 56:1122-1128.
30. Chen L., Shi Y., Jiang C.Y., et al. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers 2011, 26:108-116.
31. Yang X.R., Xu Y., Yu B., et al. High expression levels of putative hepatic stem/progenitor cell markers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010, 59:953-962.
32. Wu L.M., Xie H.Y., Zhou L., et al. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res 2009, 40:565-570.
33. Trevisani F., De Notariis S., Rossi C., Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?. J Clin Gastroenterol 2001, 32:383-389.
34. Bruix J., Sala M., Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004, 127:S179-S188.
35. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma. Chemoembolization improves survival. Hepatology 2003, 37:429-442.
36. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30:6-25.
37. Sun Z., Li G., Ai X., et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011, 79:164-174.
38. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
39. Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007, 5:1100-1108.
40. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52.
41. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334.
42. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
43. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
44. Bellmunt J., Eisen T., Fishman M., Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011, 78:24-42.
45. Schutz F.A., Je Y., Choueiri T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011, 80:291-300.
46. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100:1385-1392.
47. Shim J.H., Park J.W., Kim J.H., et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008, 99:2037-2044.
48. Poon R.T., Ng I.O., Lau C., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001, 233:227-235.
49. Poon R.T., Lau C., Pang R., et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007, 14:1835-1845.
50. von Marschall Z., Cramer T., Höcker M., et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001, 48:87-96.
51. Xiong Z.P., Yang S.R., Liang Z.Y., et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004, 3:386-390.
52. Sergio A., Cristofori C., Cardin R., et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008, 103:914-921.
53. Li X., Feng G.S., Zheng C.S., Zhuo C.K., Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004, 10:2878-2882.
54. Wang B., Xu H., Gao Z.Q., et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008, 49:523-529.
55. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
56. Song B.C., Chung Y.H., Kim J.A., et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 2001, 91:2386-2393.
57. Stepanova M., Hossain N., Afency A., et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg 2010, 20:640-650.
58. Strebel B.M., Dufour J.F. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008, 8:1743-1749.
59. Groupe d'étude et de Traitement du Carcinome Hepatocellulaire A comparison of lipiodol chemoembolization and conservate treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995, 332:1256-1261.
60. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
61. Pelletier G., Ducreux M., Gay F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998, 29:129-134.
62. Chung Y., Kim B., Chen C., et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis [abstract]. J Clin Oncol 2010, (28:Abstract 4026).
63. ClinicalTrials.gov. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Updated November 11, 2010. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01004978%3Fterm=sorafenib+ecog+1208%26rank=1.
64. UK Clinical Research Network: Portfolio Database. TACE-2-a randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Available at: http://public.ukcrn.org.uk/search/StudyDetail.aspx%3FStudyID=5347.
65. Hoffmann K., Glimm H., Radeleff B., et al. Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008, 8:349.
66. Lencioni R., Zou J., Leberre M., et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE) [abstract]. J Clin Oncol 2010, (28:Abstract TPS178).
67. Gadaleta C.D., Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combinations with angiogenesis inhibitors. Crit Rev Oncol Hematol 2011, 80:40-53.
68. Lin D.Y., Liaw Y.F., Lee T.Y., Lai C.M. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988, 94:453-456.
69. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990, 11:181-184.
70. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998, 27:1578-1583.